{"id":7641,"date":"2020-10-30T15:02:42","date_gmt":"2020-10-30T15:02:42","guid":{"rendered":"https:\/\/www.marrow.com\/blog\/?p=7641"},"modified":"2020-11-05T18:48:33","modified_gmt":"2020-11-05T18:48:33","slug":"newsletter-vol-1-issue-9","status":"publish","type":"post","link":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/","title":{"rendered":"QBank Fortnightly Newsletter Vol: 1, Issue: 9"},"content":{"rendered":"\n<figure class=\"wp-block-gallery columns-1 is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\"><ul class=\"blocks-gallery-grid\"><li class=\"blocks-gallery-item\"><figure><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"488\" src=\"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1024x488.jpg\" alt=\"\" data-id=\"7660\" data-full-url=\"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23.jpg\" data-link=\"https:\/\/www.marrow.com\/blog\/?attachment_id=7660\" class=\"wp-image-7660\" srcset=\"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1024x488.jpg 1024w, https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-300x143.jpg 300w, https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-768x366.jpg 768w, https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1536x732.jpg 1536w, https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23.jpg 1751w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/li><\/ul><\/figure>\n\n\n\n<div class=\"wp-block-group has-very-dark-gray-color has-text-color\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><em>Hello!&nbsp;<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>We are back with more interesting updates.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>This time we talk about the recent American Heart Association (AHA) updates, the first drug approved for Ebola, and more updates from the latest edition of Robbins. Please take a look.<\/em><\/p>\n<\/div><\/div>\n\n\n\n<p class=\"has-small-font-size wp-block-paragraph\"><em>To find the relevant MCQs, copy the MCQ IDs given under each topic and search for them in the Marrow app<\/em>.<\/p>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group has-very-light-gray-background-color has-very-dark-gray-color has-text-color has-background\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<h4 class=\"has-text-color wp-block-heading\" style=\"color:#21546a\"><strong>1. FDA approves first treatment for Ebola virus<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><mark>MCQ ID -MA8139<\/mark><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On 14th October 2020, the U.S. Food and Drug Administration (FDA) approved<strong> Inmazeb<\/strong> (Atoltivimab, Maftivimab, and Odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for<strong> Zaire ebolavirus<\/strong> (Ebola virus) infection in adult and pediatric patients.<\/p>\n<\/div><\/div>\n\n\n\n<p class=\"has-small-font-size wp-block-paragraph\">Reference-<a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-ebola-virus\" target=\"_blank\" aria-label=\"undefined (opens in a new tab)\" rel=\"noreferrer noopener\">https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-ebola-virus<\/a><\/p>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group has-very-light-gray-background-color has-background\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<h4 class=\"has-text-color wp-block-heading\" style=\"color:#21546a\"><strong>2. American Heart Association (AHA) guidelines for CPR and ECC 2020<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><mark>MCQ ID- MD5884| MD5883| MD5881. Pearl ID- 188<\/mark><\/strong><\/p>\n\n\n\n<p style=\"color:#21546a\" class=\"has-text-color wp-block-paragraph\"><strong><span style=\"text-decoration: underline;\">Adult Basic and Advanced life support:<\/span><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>&nbsp;A sixth link, \u2018recovery\u2019 has been added to all 4 chains of survival<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">IHCA (In-hospital cardiac arrest) chain of survival includes:<\/p>\n\n\n\n<ol class=\"wp-block-list\"><li>Early recognition and prevention&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/li><li>Activation of emergency response<\/li><li>High-quality CPR<\/li><li>Defibrillator<\/li><li>Post cardiac arrest care<\/li><li>Recovery<\/li><\/ol>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Double sequential defibrillation not supported<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The usefulness of double sequential defibrillation for refractory shockable rhythm has not been established.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Early administration of epinephrine<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">With respect to timing, for cardiac arrest with a non-shockable rhythm, it is reasonable to administer epinephrine as soon as feasible.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Early Initiation of CPR by Lay Rescuers<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;AHA recommends that laypersons initiate CPR for presumed cardiac arrest because the risk of harm to the patient is low even if the patient is not in cardiac arrest.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Real-Time Audiovisual Feedback<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">It may be reasonable to use audiovisual feedback devices during CPR for real-time optimization of CPR performance.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Cardiac Arrest in Pregnancy<\/strong><\/li><\/ul>\n\n\n\n<ol class=\"wp-block-list\"><li>As pregnant patients are more prone to hypoxia, oxygenation and <strong>airway management<\/strong> should be <strong>prioritized<\/strong> during resuscitation from cardiac arrest in pregnancy.<\/li><li>Because of potential interference with maternal resuscitation, <strong>fetal monitoring <\/strong>should not be undertaken during cardiac arrest in pregnancy.<\/li><li>The AHA recommends <strong>targeted temperature<\/strong> management for pregnant women who remain comatose after resuscitation from cardiac arrest.<\/li><li>During targeted temperature management of the pregnant patient, it is recommended that the <strong>fetus be continuously monitored for bradycardia<\/strong> as a potential complication, and obstetric and neonatal consultation should be sought.<\/li><\/ol>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>&nbsp;IV Access Preferred Over IO<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">It is reasonable for providers first to attempt establishing IV access for drug administration in cardiac arrest. Intraosseous (IO)access may be considered if attempts at IV access are unsuccessful or not feasible.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Post\u2013Cardiac Arrest Care and Neuroprognostication<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Neuroprognostication should be performed no sooner than 72 hours after return to normothermia, and prognostic decisions should be based on multiple modes of patient assessment. EEG, neurological imaging is introduced as part of post-resuscitation care.<\/p>\n\n\n\n<p style=\"color:#21546a\" class=\"has-text-color wp-block-paragraph\"><strong><span style=\"text-decoration: underline;\">Pediatric Basic and advanced life support<\/span><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Cuffed ETTs<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">It is reasonable to choose cuffed ETTs over uncuffed ETTs for intubating infants and children. When a cuffed ETT is used, attention should be paid to ETT size, position, and cuff inflation pressure (usually &lt;20-25 cm H2O).<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Changes to the Assisted Ventilation Rate: Rescue Breathing<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For infants and children with a pulse but an absent or inadequate respiratory effort, it is reasonable to give 1 breath every 2 to 3 seconds (20-30 breaths\/min).<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Cricoid Pressure During Intubation<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Routine use of cricoid pressure is not recommended during the endotracheal intubation of pediatric patients.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Emphasis on Early Epinephrine Administration<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For pediatric patients in any setting, it is reasonable to administer the initial dose of epinephrine within 5 minutes from the start of chest compressions.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Corticosteroid Administration<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For infants and children with septic shock unresponsive to fluids and requiring vasoactive support, it may be reasonable to consider stress-dose corticosteroids.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>A new algorithm for pediatric tachycardia with a pulse (QRS duration 0.09 sec)<\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">A wide QRS duration of &gt;0.09 second is suggestive of possible ventricular tachycardia.<\/p>\n<\/div><\/div>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:12px\"><strong>Reference-<\/strong><a href=\"https:\/\/cpr.heart.org\/-\/media\/cpr-files\/cpr-guidelines-files\/highlights\/hghlghts_2020_ecc_guidelines_english.pdf\" target=\"_blank\" aria-label=\"undefined (opens in a new tab)\" rel=\"noreferrer noopener\"><strong>https:\/\/cpr.heart.org\/-\/media\/cpr-files\/cpr-guidelines-files\/highlights\/hghlghts_2020_ecc_guidelines_english.pdf<\/strong><\/a><\/p>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group has-very-light-gray-background-color has-very-dark-gray-color has-text-color has-background\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<h4 class=\"has-text-color wp-block-heading\" style=\"color:#21546a\"><strong>3. X-linked osteopetrosis<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><mark>MCQ ID- MD5880<\/mark><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Osteopetrosis<\/strong> can have an <strong>X-linked<\/strong> pattern of inheritance. It occurs due to<strong> <em>IKBKG <\/em>mutation<\/strong> which encodes NEMO. It is involved in <strong><em>NF-kB<\/em> activation<\/strong>. Because NF-kB serves many other functions, <em>IKBKG <\/em>mutations result in a multisystem disorder called X-linked <strong>anhidrotic ectodermal dysplasia<\/strong> with immunodeficiency, which includes osteopetrosis.<\/p>\n<\/div><\/div>\n\n\n\n<p style=\"color:#04639a\" class=\"has-text-color has-small-font-size wp-block-paragraph\">Reference- Robbins and Cotran 10th edition, page no 1177<\/p>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group has-very-light-gray-background-color has-background\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<h4 class=\"has-text-color wp-block-heading\" style=\"color:#21546a\"><strong>4. Occluding junctions (tight junction)<\/strong><\/h4>\n\n\n\n<p class=\"has-text-align-left wp-block-paragraph\"><strong><mark>MCQ ID- MB9305<\/mark><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">According to Robbins and Cotran 10th edition, complexes that mediate the tight junctions are composed of transmembrane proteins including the <strong>claudin<\/strong> and<strong> tight junction-associated MARVEL protein (TAMP) families<\/strong>. These connect to a host of intracellular adaptor and scaffolding proteins, including the three members of the zonula occludens protein family (ZO-1, ZO-2, ZO-3) and cingulin.<\/p>\n<\/div><\/div>\n\n\n\n<p style=\"color:#04639a\" class=\"has-text-color has-small-font-size wp-block-paragraph\">Reference- Robbins and Cotran 10th edition, Page no 12<\/p>\n<\/div><\/div>\n\n\n\n<hr class=\"wp-block-separator is-style-wide\"\/>\n\n\n\n<div class=\"wp-block-group has-background\" style=\"background-color:#fefbd3\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong><em>Get the latest updated QBank MCQs from the Marrow Facebook page.&nbsp;<strong><em><a href=\"http:\/\/bit.ly\/MarrowFBpage\" target=\"_blank\" rel=\"noreferrer noopener\">\u2018Like\u2019 us by clicking here<\/a>\u2013&nbsp;<\/em><\/strong>One MCQ every day.<\/em><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><em>To see the previous issues of the newsletter,&nbsp;<a href=\"https:\/\/www.marrow.com\/blog\/category\/qbank-fortnightly-newsletters-recent-updates\/\">click here<\/a><\/em><\/strong><\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>This time we talk about the recent American Heart Association (AHA) updates, the first drug approved for Ebola, and more updates from the latest edition of Robbins. Please take a look.<\/p>\n","protected":false},"author":27,"featured_media":7663,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","_exactmetrics_skip_tracking":false,"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[595],"tags":[],"class_list":["post-7641","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-qbank-fortnightly-newsletters-recent-updates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>QBank Fortnightly Newsletter Vol: 1, Issue: 9 -<\/title>\n<meta name=\"description\" content=\"Hello! We are back with more interesting updates. This time we talk about the recent American Heart Association (AHA) updates, the first drug approved for Ebola, and more updates from the latest edition of Robbins. Please take a look.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"QBank Fortnightly Newsletter Vol: 1, Issue: 9 -\" \/>\n<meta property=\"og:description\" content=\"Hello! We are back with more interesting updates. This time we talk about the recent American Heart Association (AHA) updates, the first drug approved for Ebola, and more updates from the latest edition of Robbins. Please take a look.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marrowmed\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-30T15:02:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-05T18:48:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1751\" \/>\n\t<meta property=\"og:image:height\" content=\"834\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Team Marrow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Team Marrow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/\"},\"author\":{\"name\":\"Team Marrow\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#\\\/schema\\\/person\\\/cd6a97d1afd5417c0e14c18b3c4f4f0a\"},\"headline\":\"QBank Fortnightly Newsletter Vol: 1, Issue: 9\",\"datePublished\":\"2020-10-30T15:02:42+00:00\",\"dateModified\":\"2020-11-05T18:48:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/\"},\"wordCount\":827,\"commentCount\":38,\"publisher\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/Newsletter-Thumbnail-Issue-8-23-1.jpg\",\"articleSection\":[\"QBank Newsletters\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/\",\"name\":\"QBank Fortnightly Newsletter Vol: 1, Issue: 9 -\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/Newsletter-Thumbnail-Issue-8-23-1.jpg\",\"datePublished\":\"2020-10-30T15:02:42+00:00\",\"dateModified\":\"2020-11-05T18:48:33+00:00\",\"description\":\"Hello! We are back with more interesting updates. This time we talk about the recent American Heart Association (AHA) updates, the first drug approved for Ebola, and more updates from the latest edition of Robbins. Please take a look.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/Newsletter-Thumbnail-Issue-8-23-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/Newsletter-Thumbnail-Issue-8-23-1.jpg\",\"width\":1751,\"height\":834},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/newsletter-vol-1-issue-9\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"QBank Fortnightly Newsletter Vol: 1, Issue: 9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/\",\"name\":\"Marrow\",\"description\":\"The Gold Standard for new pattern NEET PG - NEXT\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#organization\",\"name\":\"Marrow\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/image-2.png\",\"contentUrl\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/image-2.png\",\"width\":1024,\"height\":1024,\"caption\":\"Marrow\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/marrowmed\\\/\",\"https:\\\/\\\/www.instagram.com\\\/marrowmed\\\/?hl=en\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCkdqtg0tEcRb1wMCFr2wN2A\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#\\\/schema\\\/person\\\/cd6a97d1afd5417c0e14c18b3c4f4f0a\",\"name\":\"Team Marrow\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/author\\\/kishan-shob\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"QBank Fortnightly Newsletter Vol: 1, Issue: 9 -","description":"Hello! We are back with more interesting updates. This time we talk about the recent American Heart Association (AHA) updates, the first drug approved for Ebola, and more updates from the latest edition of Robbins. Please take a look.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/","og_locale":"en_US","og_type":"article","og_title":"QBank Fortnightly Newsletter Vol: 1, Issue: 9 -","og_description":"Hello! We are back with more interesting updates. This time we talk about the recent American Heart Association (AHA) updates, the first drug approved for Ebola, and more updates from the latest edition of Robbins. Please take a look.","og_url":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/","article_publisher":"https:\/\/www.facebook.com\/marrowmed\/","article_published_time":"2020-10-30T15:02:42+00:00","article_modified_time":"2020-11-05T18:48:33+00:00","og_image":[{"width":1751,"height":834,"url":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1.jpg","type":"image\/jpeg"}],"author":"Team Marrow","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Team Marrow","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/#article","isPartOf":{"@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/"},"author":{"name":"Team Marrow","@id":"https:\/\/www.marrow.com\/blog\/#\/schema\/person\/cd6a97d1afd5417c0e14c18b3c4f4f0a"},"headline":"QBank Fortnightly Newsletter Vol: 1, Issue: 9","datePublished":"2020-10-30T15:02:42+00:00","dateModified":"2020-11-05T18:48:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/"},"wordCount":827,"commentCount":38,"publisher":{"@id":"https:\/\/www.marrow.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/#primaryimage"},"thumbnailUrl":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1.jpg","articleSection":["QBank Newsletters"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/","url":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/","name":"QBank Fortnightly Newsletter Vol: 1, Issue: 9 -","isPartOf":{"@id":"https:\/\/www.marrow.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/#primaryimage"},"image":{"@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/#primaryimage"},"thumbnailUrl":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1.jpg","datePublished":"2020-10-30T15:02:42+00:00","dateModified":"2020-11-05T18:48:33+00:00","description":"Hello! We are back with more interesting updates. This time we talk about the recent American Heart Association (AHA) updates, the first drug approved for Ebola, and more updates from the latest edition of Robbins. Please take a look.","breadcrumb":{"@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/#primaryimage","url":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1.jpg","contentUrl":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1.jpg","width":1751,"height":834},{"@type":"BreadcrumbList","@id":"https:\/\/www.marrow.com\/blog\/newsletter-vol-1-issue-9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marrow.com\/blog\/"},{"@type":"ListItem","position":2,"name":"QBank Fortnightly Newsletter Vol: 1, Issue: 9"}]},{"@type":"WebSite","@id":"https:\/\/www.marrow.com\/blog\/#website","url":"https:\/\/www.marrow.com\/blog\/","name":"Marrow","description":"The Gold Standard for new pattern NEET PG - NEXT","publisher":{"@id":"https:\/\/www.marrow.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marrow.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.marrow.com\/blog\/#organization","name":"Marrow","url":"https:\/\/www.marrow.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marrow.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2018\/02\/image-2.png","contentUrl":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2018\/02\/image-2.png","width":1024,"height":1024,"caption":"Marrow"},"image":{"@id":"https:\/\/www.marrow.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marrowmed\/","https:\/\/www.instagram.com\/marrowmed\/?hl=en","https:\/\/www.youtube.com\/channel\/UCkdqtg0tEcRb1wMCFr2wN2A"]},{"@type":"Person","@id":"https:\/\/www.marrow.com\/blog\/#\/schema\/person\/cd6a97d1afd5417c0e14c18b3c4f4f0a","name":"Team Marrow","url":"https:\/\/www.marrow.com\/blog\/author\/kishan-shob\/"}]}},"jetpack_publicize_connections":[],"uagb_featured_image_src":{"full":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1.jpg",1751,834,false],"thumbnail":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-150x150.jpg",150,150,true],"medium":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-300x143.jpg",300,143,true],"medium_large":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-768x366.jpg",768,366,true],"large":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-1024x488.jpg",700,334,true],"1536x1536":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-1536x732.jpg",1536,732,true],"2048x2048":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1.jpg",1751,834,false],"thumb-small":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-160x160.jpg",80,80,true],"thumb-standard":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-320x320.jpg",320,320,true],"thumb-medium":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-520x245.jpg",520,245,true],"thumb-large":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-720x340.jpg",720,340,true],"thumb-xlarge":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-980x450.jpg",980,450,true],"thumb-xxlarge":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1-1320x500.jpg",1320,500,true]},"uagb_author_info":{"display_name":"Team Marrow","author_link":"https:\/\/www.marrow.com\/blog\/author\/kishan-shob\/"},"uagb_comment_info":167,"uagb_excerpt":"This time we talk about the recent American Heart Association (AHA) updates, the first drug approved for Ebola, and more updates from the latest edition of Robbins. Please take a look.","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pawmxr-1Zf","jetpack_featured_media_url":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2020\/10\/Newsletter-Thumbnail-Issue-8-23-1.jpg","_links":{"self":[{"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/posts\/7641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/comments?post=7641"}],"version-history":[{"count":21,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/posts\/7641\/revisions"}],"predecessor-version":[{"id":7672,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/posts\/7641\/revisions\/7672"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/media\/7663"}],"wp:attachment":[{"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/media?parent=7641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/categories?post=7641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/tags?post=7641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}